NCT00556998 - A Multiple-Dose Study To Evaluate The Pharmacokinetics And Safety Of Voriconazole In Immunocompromised Adolescents | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions

Pharmacokinetics

Interventions

DRUG

Voriconazole

Voriconazole will be used for prophylaxis purpose. 6 mg/kg IV q12h on the first day (Day 1) and 4 mg/kg IV q12h for at least 5.5 days. The IV treatment is no more than 20 days. Then switch to 300 mg oral tablets q12h for at least 6.5 days. The total treatment duration is no more than 30 days.

Trial Locations (9)

27705

Pfizer Investigational Site, Durham

37232

Pfizer Investigational Site, Nashville

44106

Pfizer Investigational Site, Cleveland

60637

Pfizer Investigational Site, Chicago

70118

Pfizer Investigational Site, New Orleans

77030

Pfizer Investigational Site, Houston

97239

Pfizer Investigational Site, Portland

37232-2195

Pfizer Investigational Site, Nashville

76104-2796

Pfizer Investigational Site, Fort Worth